[{"id":"5bdc28e5-7ca8-447b-ae67-6e292adebde6","acronym":"TRIFOUR","url":"https://clinicaltrials.gov/study/NCT05181462","created_at":"2022-01-06T22:53:40.626Z","updated_at":"2025-02-25T15:12:31.656Z","phase":"Phase 1/2","brief_title":"Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.","source_id_and_acronym":"NCT05181462 - TRIFOUR","lead_sponsor":"Cantargia AB","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • nadunolimab (CAN04)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-13"}]